Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Peter C. Farrell, Chairman Emeritus and Director of ResMed Inc . (NYSE:RMD), recently sold 2,000 shares of the company’s common stock. The transaction, executed on April 2, 2025, was part of a pre-arranged trading plan under Rule 10b5-1, which Farrell adopted on May 28, 2024. The shares were sold at a price of $219.74 each, totaling $439,480. Following this sale, Farrell retains ownership of 73,218 shares of ResMed stock. According to InvestingPro analysis, ResMed currently appears undervalued, with a market capitalization of $30.48 billion and maintains a perfect Piotroski Score of 9, indicating strong financial performance.
ResMed, a leader in the development of products for the treatment of respiratory disorders, is headquartered in San Diego, California. The company continues to be a significant player in the medical instruments and apparatus industry. With an "GREAT" financial health rating and a 13-year track record of consecutive dividend increases, ResMed demonstrates strong operational performance. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report, offering deeper analysis of ResMed’s market position and growth potential.
In other recent news, ResMed reported its Q2 FY2025 earnings, surpassing analyst forecasts with an earnings per share (EPS) of $2.43, compared to the expected $2.32. The company also exceeded revenue projections, achieving $1.28 billion against an anticipated $1.27 billion. Despite these strong earnings, ResMed’s stock experienced a decline in after-hours trading. Additionally, ResMed was added to Goldman Sachs’ APAC Director’s Cut Conviction List, indicating a positive outlook from the investment bank. The company is expected to see strong patient growth in Continuous Airway Pressure Therapy due to increased awareness of Obstructive Sleep Apnea (OSA). On the analyst front, Citi upgraded ResMed’s stock rating from Neutral to Buy, citing strong expected EPS growth and robust free cash flow generation. Meanwhile, Stifel adjusted its price target for ResMed to $240, maintaining a Hold rating, due to anticipated challenges in the CPAP market from the rising use of GLP-1 drugs. These developments reflect a mix of optimism and caution in ResMed’s market environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.